Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma

@article{Li2017PhaseIS,
  title={Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma},
  author={Jia Li and Xiaopan Yao and Jeremy S. Kortmansky and Neal A. Fischbach and Stacey M. Stein and Yan-ming Deng and Yue Zhang and Indukala Doddamane and David Karimeddini and Howard S. Hochster and Jill Lacy},
  journal={American Journal of Clinical Oncology},
  year={2017},
  volume={40},
  pages={146–151}
}
  • Jia Li, X. Yao, J. Lacy
  • Published 1 April 2017
  • Medicine
  • American Journal of Clinical Oncology
Background: The median survival for patients with metastatic gastroesophageal adenocarcinoma is <12 months. Bevacizumab has demonstrated promising activity in metastatic gastroesophageal adenocarcinoma when used in combination with cisplatin-based regimens for patients from the Americas. We conducted a prospective phase II trial to investigate the efficacy of bevacizumab in combination with the oxaliplatin-based regimen, modified FOLFOX6, in patients with metastatic gastroesophageal… 
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers
TLDR
The combination of gem citabine, nab-paclitaxel, and bevacizumab is safe, well-tolerated, and has activity in advanced malignancies, including gemcitabine-refractory tumours.
Anti‐angiogenic therapies for gastric cancer
  • S. Hironaka
  • Biology, Medicine
    Asia-Pacific journal of clinical oncology
  • 2019
TLDR
Preliminary results of studies investigating ramucirumab plus immune checkpoint inhibitors in gastric cancer were encouraging, and further investigations are ongoing, providing hope for improved survival in patients with Gastric cancer.
Gastric cancer: Basic aspects
TLDR
The most recent advances in understanding of GC biology are reviewed, which are underlying the development and clinical testing of novel targeted therapeutic agents and how their efficacy and acquired resistance relate to the aberrant molecular signatures that drive gastric malignancy.
Presentation and Diagnosis of Hypersensitivity to Platinum Drugs
TLDR
Platinum specific IgE measurement and basophil activation test are emerging as new diagnostic tools and in combination with skin testing can help support the diagnosis and the cross-reactivity between the three most commonly used platinum drugs, namely carboplatin, cisplatin, and oxaliplatin.

References

SHOWING 1-10 OF 32 REFERENCES
A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.
TLDR
Bvacizumab can be given safely with chemotherapy in patients with metastatic esophagogastric adenocarcinomas and has activity comparable to other bevacIZumab-containing regimens in metastatic gastroesophageal cancer.
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
  • M. Shah, R. Ramanathan, D. Kelsen
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
TLDR
Bvacizumab can be safely given with chemotherapy even with primary gastric and GEJ tumors in place, with response rate, time to disease progression (TTP), and overall survival are encouraging, with TTP improved over historical controls by 75%.
Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.
  • M. Shah, M. Jhawer, D. Kelsen
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
TLDR
mDCF with bevacizumab appears tolerable and has notable patient outcomes in patients with advanced gastroesophageal adenocarcinoma, surpassing the authors' predefined efficacy end point.
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
TLDR
In older adult patients, FLO also seemed to be associated with improved efficacy in patients with advanced gastric cancer, and in patients older than 65 years, this study found that FLO reduced toxicity as compared with FLP.
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
  • B. Giantonio, P. Catalano, A. Benson
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2007
TLDR
The addition of bevacizumab to oxaliplatin, fluorouracil, and leucovorin improves survival duration for patients with previously treated metastatic colorectal cancer.
Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.
  • J. Ajani, W. Rodriguez, S. Falcón
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
TLDR
CisPlatin/S-1 did not prolong OS of patients with advanced gastric or gastroesophageal adenocarcinoma compared with cisplatin/infusional fluorouracil, but it did result in a significantly improved safety profile.
A Retrospective Study of the Safety and Efficacy of a First-Line Treatment with Modified FOLFOX-4 in Unresectable Advanced or Recurrent Gastric Cancer Patients
TLDR
The mFOLFOX-4 therapy is an effective and safe first-line treatment for unresectable advanced or recurrent gastric cancer patients and was well tolerated and effective in both nonelderly and elderly patients.
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.
TLDR
Plasma VEGF-A and tumor neuropilin-1 are strong biomarker candidates for predicting clinical outcome in patients with advanced gastric cancer treated with bevacizumab, and subgroup analyses demonstrated significance only in patients from non-Asian regions.
Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group.
  • N. Starling, Sheela Rao, A. Norman
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
This analysis has prospectively quantified the incidence/pattern of TEs among patients with advanced gastroesophageal cancer who were treated with four triplet regimens, has demonstrated a differential thrombogenic effect according to platinum use, and has noted a poorer outcome associated with TE during treatment.
...
1
2
3
4
...